{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:28:05Z","timestamp":1792157285143,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00277-023-05373-5","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T08:01:46Z","timestamp":1690012906000},"page":"3133-3141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring"],"prefix":"10.1007","volume":"102","author":[{"given":"Taylor D.","family":"Coe-Eisenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard L.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L.","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6828-8053","authenticated-orcid":false,"given":"Lydia","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"5373_CR1","unstructured":"National cancer institute surveillance, epidemiology, and end results (SEER) program. Leukemia - acute lymphocytic leukemia. https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html. Accessed 20 July 2023"},{"issue":"14","key":"5373_CR2","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","volume":"133","author":"W Stock","year":"2019","unstructured":"Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG et al (2019) A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood 133(14):1548\u20131559. https:\/\/doi.org\/10.1182\/blood-2018-10-881961","journal-title":"Blood"},{"issue":"2","key":"5373_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","volume":"5","author":"AS Advani","year":"2021","unstructured":"Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M et al (2021) Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv 5(2):504\u2013512. https:\/\/doi.org\/10.1182\/bloodadvances.2020002439","journal-title":"Blood Adv"},{"issue":"3","key":"5373_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1080\/10428194.2019.1680839","volume":"61","author":"BA Derman","year":"2020","unstructured":"Derman BA, Streck M, Wynne J, Christ TN, Curran E, Stock W et al (2020) Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma 61(3):614\u2013622. https:\/\/doi.org\/10.1080\/10428194.2019.1680839","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"5373_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/jha2.224","volume":"2","author":"AA Patel","year":"2021","unstructured":"Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS et al (2021) Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem 2(3):413\u2013420. https:\/\/doi.org\/10.1002\/jha2.224","journal-title":"EJHaem"},{"issue":"12","key":"5373_CR6","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1080\/10428194.2019.1608530","volume":"60","author":"BL Marini","year":"2019","unstructured":"Marini BL, Brown J, Benitez L, Walling E, Hutchinson RJ, Mody R et al (2019) A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma 60(12):2854\u20132868. https:\/\/doi.org\/10.1080\/10428194.2019.1608530","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"5373_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/10428194.2017.1349902","volume":"59","author":"CR Rausch","year":"2018","unstructured":"Rausch CR, Marini BL, Benitez LL, Elias A, Burke PW, Bixby D et al (2018) PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. Leuk Lymphoma 59(3):617\u2013624. https:\/\/doi.org\/10.1080\/10428194.2017.1349902","journal-title":"Leuk Lymphoma"},{"key":"5373_CR8","unstructured":"Granger Genetics: L-asparaginase assay for leukemia patients. https:\/\/www.grangergenetics.com\/asparaginase. Accessed 20 July 2023"},{"issue":"12","key":"5373_CR9","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","volume":"52","author":"W Stock","year":"2011","unstructured":"Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L et al (2011) Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 52(12):2237\u20132253. https:\/\/doi.org\/10.3109\/10428194.2011.596963","journal-title":"Leuk Lymphoma"},{"key":"5373_CR10","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.\u00a0NCI, NIH, DHHS.\u00a0https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 20 July 2023"},{"issue":"23","key":"5373_CR11","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123(23):2736\u20132747. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449","journal-title":"Circulation."},{"issue":"9","key":"5373_CR12","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","volume":"18","author":"BO Wolthers","year":"2017","unstructured":"Wolthers BO, Frandsen TL, Baruchel A, Attarbaschi A, Barzilai S, Colombini A et al (2017) Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol 18(9):1238\u20131248. https:\/\/doi.org\/10.1016\/S1470-2045(17)30424-2","journal-title":"Lancet Oncol"},{"key":"5373_CR13","unstructured":"IBM Corp (2019) IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp"},{"issue":"7","key":"5373_CR14","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","volume":"109","author":"D Douer","year":"2007","unstructured":"Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP et al (2007) Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109(7):2744\u20132750. https:\/\/doi.org\/10.1182\/blood-2006-07-035006","journal-title":"Blood"},{"issue":"8","key":"5373_CR15","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P et al (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85(8):2025\u20132037","journal-title":"Blood"},{"issue":"28","key":"5373_CR16","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z et al (2020) Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol 38(28):3282\u20133293. https:\/\/doi.org\/10.1200\/JCO.20.00256","journal-title":"J Clin Oncol"},{"issue":"3","key":"5373_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2014.229","volume":"29","author":"DJ DeAngelo","year":"2015","unstructured":"DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG et al (2015) Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29(3):526\u2013534. https:\/\/doi.org\/10.1038\/leu.2014.229","journal-title":"Leukemia"},{"issue":"26","key":"5373_CR18","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1182\/blood-2014-08-595389","volume":"124","author":"E Orgel","year":"2014","unstructured":"Orgel E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH et al (2014) Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood 124(26):3932\u20133938. https:\/\/doi.org\/10.1182\/blood-2014-08-595389","journal-title":"Blood"},{"issue":"13","key":"5373_CR19","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/blood-2006-05-024414","volume":"108","author":"N Hijiya","year":"2006","unstructured":"Hijiya N, Panetta JC, Zhou Y, Kyzer EP, Howard SC, Jeha S et al (2006) Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 108(13):3997\u20134002. https:\/\/doi.org\/10.1182\/blood-2006-05-024414","journal-title":"Blood"},{"issue":"10","key":"5373_CR20","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1158\/1940-6207.CAPR-10-0087","volume":"3","author":"JP Yun","year":"2010","unstructured":"Yun JP, Behan JW, Heisterkamp N, Butturini A, Klemm L, Ji L et al (2010) Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models. Cancer Prev Res (Phila) 3(10):1259\u20131264. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-10-0087","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"5373_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","volume":"44","author":"VI Avramis","year":"2005","unstructured":"Avramis VI, Panosyan EH (2005) Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44(4):367\u2013393. https:\/\/doi.org\/10.2165\/00003088-200544040-00003","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"5373_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2362.1988.tb01049.x","volume":"18","author":"G Ollenschl\u00e4ger","year":"1988","unstructured":"Ollenschl\u00e4ger G, Roth E, Linkesch W, Jansen S, Simmel A, M\u00f6dder B (1988) Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 18(5):512\u2013516. https:\/\/doi.org\/10.1111\/j.1365-2362.1988.tb01049.x","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"5373_CR23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/pbc.25455","volume":"62","author":"LB Colon","year":"2015","unstructured":"Colon LB, Perissinotti A, Santarosa M, Marini BL (2015) Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. Pediatr Blood Cancer 62(6):1116. https:\/\/doi.org\/10.1002\/pbc.25455","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"5373_CR24","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1080\/10428194.2018.1542146","volume":"60","author":"RJ Schore","year":"2019","unstructured":"Schore RJ, Devidas M, Bleyer A, Reaman GH, Winick N, Loh ML et al (2019) Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. Leuk Lymphoma 60(7):1740\u20131748. https:\/\/doi.org\/10.1080\/10428194.2018.1542146","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"5373_CR25","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1080\/10428194.2017.1386305","volume":"59","author":"W Salzer","year":"2018","unstructured":"Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, Marini B (2018) Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma 59(8):1797\u20131806. https:\/\/doi.org\/10.1080\/10428194.2017.1386305","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5373_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/10428194.2020.1824068","volume":"62","author":"RJ Daley","year":"2021","unstructured":"Daley RJ, Rajeeve S, Kabel CC, Pappacena JJ, Stump SE, Lavery JA et al (2021) Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia. Leuk Lymphoma 62(1):176\u2013184. https:\/\/doi.org\/10.1080\/10428194.2020.1824068","journal-title":"Leuk Lymphoma"},{"key":"5373_CR27","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood-2022-171751","volume":"140","author":"MR Litzow","year":"2022","unstructured":"Litzow MR, Sun Z, Paietta E, Mattison RJ, Lazarus HM et al (2022) Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with b-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial. Blood 140:LBA-1","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05373-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05373-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05373-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:02:42Z","timestamp":1697058162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05373-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5373"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05373-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"8 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Taylor Coe-Eisenberg, PharmD, declares no conflict of interest. Anthony J. Perissinotti, PharmD, has consulted or Servier, Amgen, and Pfizer pharmaceuticals. Bernard L. Marini, PharmD, has consulted for Servier. Kristen M. Pettit, MD, provides advising for the following companies: Kura Oncology, PharmaEssentia, CTI Biopharma. Dale L. Bixby, MD, Ph.D., declares no conflict of interest. Patrick W. Burke, MD, declares no conflict of interest. Lydia L. Benitez, PharmD, declares no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}